Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma

Andres Forero-Torres, Nancy Bartlett, Anne Beaven, Han Myint, Sunita Nasta, Donald W Northfelt, Nancy C. Whiting, Jonathan G. Drachman, Albert F. Lobuglio, Craig H. Moskowitz

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Dacetuzumab, a CD40-targeted, humanized antibody, mediates antitumor activity through effector cell functions and direct apoptotic signal transduction. Preclinical studies demonstrated synergistic activity between dacetuzumab, gemcitabine and rituximab against non-Hodgkin lymphoma in vivo. A phase 1b safety/efficacy study of dacetuzumab in combination with rituximab and gemcitabine was conducted in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received dacetuzumab at doses of 8 or 12 mg/kg IV weekly with rituximab (375 mg/m2 IV weekly in cycle 1, then every 28 days) and gemcitabine (1000 mg/m2 IV, days 1, 8 and 15, or days 1 and 15). Thirty-three patients with a median age of 67 years were enrolled. Common adverse events (≥15%) were grade 1/2 cytokine release syndrome, nausea, fatigue, thrombocytopenia, headache, decreased appetite, dyspnea, neutropenia, pyrexia, anemia, diarrhea, edema, constipation and cough. Dacetuzumab-related grade 3/4 adverse events occurred infrequently. Six of 30 evaluable patients achieved a complete response (CR) and eight a partial response (PR) per investigator assessment for an overall response rate (ORR) of 47%.

Original languageEnglish (US)
Pages (from-to)277-283
Number of pages7
JournalLeukemia and Lymphoma
Volume54
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

gemcitabine
Lymphoma, Large B-Cell, Diffuse
Antibodies, Monoclonal, Humanized
Appetite
Constipation
Neutropenia
Cough
Thrombocytopenia
Dyspnea
Non-Hodgkin's Lymphoma
Nausea
Fatigue
Headache
Anemia
Diarrhea
Signal Transduction
Edema
Fever
Research Personnel
Rituximab

Keywords

  • Antibody-based immunotherapy
  • Chemotherapeutic approaches
  • Lymphoma and Hodgkin disease

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. / Forero-Torres, Andres; Bartlett, Nancy; Beaven, Anne; Myint, Han; Nasta, Sunita; Northfelt, Donald W; Whiting, Nancy C.; Drachman, Jonathan G.; Lobuglio, Albert F.; Moskowitz, Craig H.

In: Leukemia and Lymphoma, Vol. 54, No. 2, 02.2013, p. 277-283.

Research output: Contribution to journalArticle

Forero-Torres, A, Bartlett, N, Beaven, A, Myint, H, Nasta, S, Northfelt, DW, Whiting, NC, Drachman, JG, Lobuglio, AF & Moskowitz, CH 2013, 'Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma', Leukemia and Lymphoma, vol. 54, no. 2, pp. 277-283. https://doi.org/10.3109/10428194.2012.710328
Forero-Torres, Andres ; Bartlett, Nancy ; Beaven, Anne ; Myint, Han ; Nasta, Sunita ; Northfelt, Donald W ; Whiting, Nancy C. ; Drachman, Jonathan G. ; Lobuglio, Albert F. ; Moskowitz, Craig H. / Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. In: Leukemia and Lymphoma. 2013 ; Vol. 54, No. 2. pp. 277-283.
@article{982fb62150e348cea9a9005059eb54c6,
title = "Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma",
abstract = "Dacetuzumab, a CD40-targeted, humanized antibody, mediates antitumor activity through effector cell functions and direct apoptotic signal transduction. Preclinical studies demonstrated synergistic activity between dacetuzumab, gemcitabine and rituximab against non-Hodgkin lymphoma in vivo. A phase 1b safety/efficacy study of dacetuzumab in combination with rituximab and gemcitabine was conducted in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received dacetuzumab at doses of 8 or 12 mg/kg IV weekly with rituximab (375 mg/m2 IV weekly in cycle 1, then every 28 days) and gemcitabine (1000 mg/m2 IV, days 1, 8 and 15, or days 1 and 15). Thirty-three patients with a median age of 67 years were enrolled. Common adverse events (≥15{\%}) were grade 1/2 cytokine release syndrome, nausea, fatigue, thrombocytopenia, headache, decreased appetite, dyspnea, neutropenia, pyrexia, anemia, diarrhea, edema, constipation and cough. Dacetuzumab-related grade 3/4 adverse events occurred infrequently. Six of 30 evaluable patients achieved a complete response (CR) and eight a partial response (PR) per investigator assessment for an overall response rate (ORR) of 47{\%}.",
keywords = "Antibody-based immunotherapy, Chemotherapeutic approaches, Lymphoma and Hodgkin disease",
author = "Andres Forero-Torres and Nancy Bartlett and Anne Beaven and Han Myint and Sunita Nasta and Northfelt, {Donald W} and Whiting, {Nancy C.} and Drachman, {Jonathan G.} and Lobuglio, {Albert F.} and Moskowitz, {Craig H.}",
year = "2013",
month = "2",
doi = "10.3109/10428194.2012.710328",
language = "English (US)",
volume = "54",
pages = "277--283",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma

AU - Forero-Torres, Andres

AU - Bartlett, Nancy

AU - Beaven, Anne

AU - Myint, Han

AU - Nasta, Sunita

AU - Northfelt, Donald W

AU - Whiting, Nancy C.

AU - Drachman, Jonathan G.

AU - Lobuglio, Albert F.

AU - Moskowitz, Craig H.

PY - 2013/2

Y1 - 2013/2

N2 - Dacetuzumab, a CD40-targeted, humanized antibody, mediates antitumor activity through effector cell functions and direct apoptotic signal transduction. Preclinical studies demonstrated synergistic activity between dacetuzumab, gemcitabine and rituximab against non-Hodgkin lymphoma in vivo. A phase 1b safety/efficacy study of dacetuzumab in combination with rituximab and gemcitabine was conducted in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received dacetuzumab at doses of 8 or 12 mg/kg IV weekly with rituximab (375 mg/m2 IV weekly in cycle 1, then every 28 days) and gemcitabine (1000 mg/m2 IV, days 1, 8 and 15, or days 1 and 15). Thirty-three patients with a median age of 67 years were enrolled. Common adverse events (≥15%) were grade 1/2 cytokine release syndrome, nausea, fatigue, thrombocytopenia, headache, decreased appetite, dyspnea, neutropenia, pyrexia, anemia, diarrhea, edema, constipation and cough. Dacetuzumab-related grade 3/4 adverse events occurred infrequently. Six of 30 evaluable patients achieved a complete response (CR) and eight a partial response (PR) per investigator assessment for an overall response rate (ORR) of 47%.

AB - Dacetuzumab, a CD40-targeted, humanized antibody, mediates antitumor activity through effector cell functions and direct apoptotic signal transduction. Preclinical studies demonstrated synergistic activity between dacetuzumab, gemcitabine and rituximab against non-Hodgkin lymphoma in vivo. A phase 1b safety/efficacy study of dacetuzumab in combination with rituximab and gemcitabine was conducted in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received dacetuzumab at doses of 8 or 12 mg/kg IV weekly with rituximab (375 mg/m2 IV weekly in cycle 1, then every 28 days) and gemcitabine (1000 mg/m2 IV, days 1, 8 and 15, or days 1 and 15). Thirty-three patients with a median age of 67 years were enrolled. Common adverse events (≥15%) were grade 1/2 cytokine release syndrome, nausea, fatigue, thrombocytopenia, headache, decreased appetite, dyspnea, neutropenia, pyrexia, anemia, diarrhea, edema, constipation and cough. Dacetuzumab-related grade 3/4 adverse events occurred infrequently. Six of 30 evaluable patients achieved a complete response (CR) and eight a partial response (PR) per investigator assessment for an overall response rate (ORR) of 47%.

KW - Antibody-based immunotherapy

KW - Chemotherapeutic approaches

KW - Lymphoma and Hodgkin disease

UR - http://www.scopus.com/inward/record.url?scp=84872047730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872047730&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.710328

DO - 10.3109/10428194.2012.710328

M3 - Article

C2 - 22775314

AN - SCOPUS:84872047730

VL - 54

SP - 277

EP - 283

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2

ER -